- TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
- TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
- TriSalus Reports Q1 2024 Financial Results and Business Update
- TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
- TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
- TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
- TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
- TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
- TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
- TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results
More ▼
Key statistics
On Thursday, TriSalus Life Sciences Inc (TLSI:NMQ) closed at 6.92, 108.43% above the 52 week low of 3.32 set on Nov 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.06 |
---|---|
High | 7.12 |
Low | 6.50 |
Bid | 6.74 |
Offer | 10.92 |
Previous close | 7.16 |
Average volume | 73.66k |
---|---|
Shares outstanding | 27.16m |
Free float | 12.60m |
P/E (TTM) | -- |
Market cap | 194.46m USD |
EPS (TTM) | -2.09 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 21:00 BST.
More ▼